Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.14)
# 1,214
Out of 5,051 analysts
38
Total ratings
45.16%
Success rate
4.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CADL Candel Therapeutics | Initiates: Overweight | $15 | $5.05 | +197.03% | 1 | Oct 28, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $20.01 | +74.91% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.32 | +158.62% | 3 | Sep 22, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $16 → $14 | $9.42 | +48.62% | 2 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $29.94 | +50.30% | 3 | Sep 9, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $12.12 | +147.52% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $39.24 | +52.91% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $8.79 | +184.41% | 3 | Jun 23, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $14.87 | +101.75% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $21.23 | +55.44% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.94 | +103.05% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $6.74 | +122.55% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $58.25 | +3.00% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.33 | +275.94% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $4.00 | +225.00% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.88 | +1,026.13% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.31 | +765.80% | 1 | May 14, 2024 |
Candel Therapeutics
Oct 28, 2025
Initiates: Overweight
Price Target: $15
Current: $5.05
Upside: +197.03%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $20.01
Upside: +74.91%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.32
Upside: +158.62%
Arvinas
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $14
Current: $9.42
Upside: +48.62%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $29.94
Upside: +50.30%
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $12.12
Upside: +147.52%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $39.24
Upside: +52.91%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $8.79
Upside: +184.41%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $14.87
Upside: +101.75%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $21.23
Upside: +55.44%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.94
Upside: +103.05%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $6.74
Upside: +122.55%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $58.25
Upside: +3.00%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.33
Upside: +275.94%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $4.00
Upside: +225.00%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.88
Upside: +1,026.13%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.31
Upside: +765.80%